

Published in final edited form as:

*Nat Genet.* 2017 February ; 49(2): 256–261. doi:10.1038/ng.3760.

## Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease

Katrina M. de Lange<sup>#1</sup>, Loukas Moutsianas<sup>#1</sup>, James C. Lee<sup>#2</sup>, Christopher A. Lamb<sup>3</sup>, Yang Luo<sup>1,4,5</sup>, Nicholas A. Kennedy<sup>6,7</sup>, Luke Jostins<sup>8,9</sup>, Daniel L. Rice<sup>1</sup>, Javier Gutierrez-Achury<sup>1</sup>, Sun-Gou Ji<sup>1</sup>, Graham Heap<sup>6,7</sup>, Elaine R. Nimmo<sup>10</sup>, Cathryn Edwards<sup>11</sup>, Paul Henderson<sup>12,13</sup>, Craig Mowat<sup>14</sup>, Jeremy Sanderson<sup>15</sup>, Jack Satsangi<sup>10</sup>, Alison Simmons<sup>16,17</sup>, David C. Wilson<sup>18,19</sup>, Mark Tremelling<sup>20</sup>, Ailsa Hart<sup>21</sup>, Christopher G. Mathew<sup>22,23</sup>, William G. Newman<sup>24,25</sup>, Miles Parkes<sup>2</sup>, Charlie W. Lees<sup>10</sup>, Holm Uhlig<sup>26</sup>, Chris Hawkey<sup>27</sup>, Natalie J. Prescott<sup>22</sup>, Tariq Ahmad<sup>6,7</sup>, John C. Mansfield<sup>28</sup>, Carl A. Anderson<sup>†,1</sup>, and Jeffrey C. Barrett<sup>†,1</sup>

[<sup>1</sup>] Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK

[<sup>2</sup>] Inflammatory Bowel Disease Research Group, Addenbrooke's Hospital, Cambridge, UK

[<sup>3</sup>] Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne

[<sup>4</sup>] Division of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

[<sup>5</sup>] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA

[<sup>6</sup>] Precision Medicine Exeter, University of Exeter, Exeter, UK

[<sup>7</sup>] IBD Pharmacogenetics, Royal Devon and Exeter Foundation Trust, Exeter, UK

[<sup>8</sup>] Wellcome Trust Centre for Human Genetics, University of Oxford, Headington, UK

[<sup>9</sup>] Christ Church, University of Oxford, St Aldates, UK

[<sup>10</sup>] Gastrointestinal Unit, Wester General Hospital University of Edinburgh, Edinburgh, UK

[<sup>11</sup>] Department of Gastroenterology, Torbay Hospital, Torbay, Devon, UK

[<sup>12</sup>] Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence should be addressed to Jeffrey C. Barrett (jb26@sanger.ac.uk) and Carl A. Anderson (ca3@sanger.ac.uk).

<sup>†</sup>These authors jointly supervised this work

### Author contributions

KMdL, LM, YL, LJ, DLR, CAA, and SGJ performed statistical analysis. KMdL, LM, YL, LJ, JCL, JGA, SGJ, CAL, NAK, and CAA analysed the data. GH, ERN, CE, CM, AS, DCW, MT, AH, CGM, MP, WGM, CWL, HU, CH, NJP, TA, JCM, JackS, JerS, and PH contributed samples/materials. CAA, JCB, KMdL, LM, JCL, CGM, MP, CAL, NAK, YL, and PH wrote the paper. JCB, CAA, JCM, MP, CWL, TA, and NJP conceived & designed experiments.

### Competing financial interests

The authors declare no competing financial interests.

- [13]Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK
- [14]Department of Medicine, Ninewells Hospital and Medical School, Dundee, UK
- [15]Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, Department of Gastroenterology, London, UK
- [16]Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
- [17]Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
- [18]Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK
- [19]Child Life and Health, University of Edinburgh, Edinburgh, Scotland, UK
- [20]Gastroenterology & General Medicine, Norfolk and Norwich University Hospital, Norwich, UK
- [21]Department of Medicine, St Mark's Hospital, Harrow, Middlesex, UK
- [22]Department of Medical and Molecular Genetics, Faculty of Life Science and Medicine, King's College London, Guy's Hospital, London, UK
- [23]Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of Witwatersrand, South Africa
- [24]Genetic Medicine, Manchester Academic Health Science Centre, Manchester, UK
- [25]The Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK
- [26]Translational Gastroenterology Unit and the Department of Paediatrics, University of Oxford, Oxford, United Kingdom
- [27]Nottingham Digestive Diseases Centre, Queens Medical Centre, Nottingham, UK
- [28]Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK

# These authors contributed equally to this work.

## Abstract

Genetic association studies have identified 215 risk loci for inflammatory bowel disease 1–8, which have revealed fundamental aspects of its molecular biology. We performed a genome-wide association study of 25,305 individuals, and meta-analyzed with published summary statistics, yielding a total sample size of 59,957 subjects. We identified 25 new loci, three of which contain integrin genes that encode proteins in pathways identified as important therapeutic targets in inflammatory bowel disease. The associated variants are correlated with expression changes in response to immune stimulus at two of these genes (*ITGA4*, *ITGB8*) and at previously implicated loci (*ITGAL*, *ICAM1*). In all four cases, the expression increasing allele also increases disease risk. We also identified likely causal missense variants in the primary immune deficiency gene *PLCG2* and a negative regulator of inflammation, *SLAMF8*. Our results demonstrate that new common variant associations continue to identify genes relevant to therapeutic target identification and prioritization.

Inflammatory bowel disease (IBD) is a chronic, debilitating, disorder of the gastrointestinal tract that includes two common disease subtypes, Crohn's disease and ulcerative colitis. Disease pathogenesis is poorly understood but is likely driven by a dysregulated immune response to unknown environmental triggers in genetically susceptible individuals. Treatment regimes often use potent immunomodulators to achieve and maintain remission of symptoms. However, patients commonly experience side effects, lose response to treatment, or develop complications of IBD, with many ultimately requiring major abdominal surgery. Previous genome-wide association studies (GWAS) and targeted follow-up using the ImmunoChip have been very successful at identifying genetic risk loci for IBD, but increased biological understanding has not yet had a significant impact on therapy for these disorders.

In order to further expand our understanding of the biology of these disorders we carried out a GWAS of 12,160 IBD cases and 13,145 population controls of European ancestry that had not been included in any genome-wide meta-analysis of IBD to date (Supplementary Table 1, Online Methods). We imputed genotypes using a reference panel comprising whole genome sequences from 4,686 IBD cases<sup>9</sup> and 6,285 publically available population controls<sup>10,11</sup>. Following quality control (Online Methods) we tested 9.7 million sites for association. At the 232 IBD associated SNPs in the latest meta-analysis by the International IBD Genetics Consortium<sup>1</sup>, 228 had effects in the same direction in our data, 188 showed at least nominal evidence of replication ( $P < 0.05$ ) and none showed significant evidence of heterogeneity of effect by Cochran's Q test. Among these replicated loci was a genome-wide significant association on chromosome 10q25 that was only previously significantly associated with Crohn's disease in individuals of East Asian ancestry<sup>3,7</sup>, further supporting near complete sharing of genetic risk loci across populations<sup>1</sup>. We meta-analyzed our new GWAS data with previously published summary statistics from 12,882 IBD cases and 21,770 population controls imputed using the 1000 Genomes Project reference panel<sup>1</sup> (Supplementary Figures 1-3, Supplementary Table 2). We observed inflation of the summary statistics ( $\lambda_{GC} = 1.23$  and 1.29 for Crohn's and ulcerative colitis, respectively), but LD score regression demonstrated that this was due to broad polygenic signal, rather than confounding population substructure (both intercepts = 1.09, Online Methods).

We identified 25 new loci at genome-wide significance (Table 1). In order to identify causal variants, genes and mechanisms, we performed a summary-statistic fine-mapping analysis on these loci, as well as 40 previously discovered loci that were genome-wide significant in our data but where fine-mapping had not yet been attempted<sup>12</sup> (Online Methods, Supplementary Table 3). In order to be confident about fine-mapping inferences, we restricted subsequent analyses to 12 signals where we had high quality imputed data for all relevant variants (Online Methods). At 6 of these 12 loci we identified a single variant with >50% probability of being causal (Table 2, Supplementary Figures 4-6). Among these were two loci where a single variant had >99% probability of being causal: a missense variant predicted to affect protein function in *SLAMF8*, (rs34687326, p.Gly99Ser, Figure 1a), and an intronic variant in the key regulator of Th17 cell differentiation, *RORC13*. *SLAMF8* is a cell surface receptor that is expressed on activated myeloid cells and has been reported to negatively regulate inflammatory responses by inhibiting their migration to sites of inflammation<sup>14</sup> and repressing their production of reactive oxygen species (ROS)<sup>15</sup>. This,

together with the observation that the risk-decreasing allele (MAF=0.1) is predicted to affect protein function (CADD=32.0, 92<sup>nd</sup> percentile of missense variants)<sup>16</sup>, suggests further experiments evaluating a possible gain-of-function mechanism may be worthwhile. *RORC* encodes ROR $\gamma$ t, the master transcriptional regulator of Th17 cells<sup>13</sup> and group 3 innate lymphoid cells<sup>17</sup>. Both of these cell types play important roles in defence at mucosal surfaces, especially in the intestine, and have been shown to contribute to the homeostasis between the intestinal immune system and gut microbiota<sup>18,19</sup>, an equilibrium that is known to be lost in inflammatory bowel disease<sup>20</sup>. Pharmacologic inhibition of ROR $\gamma$ t has been shown to offer therapeutic benefit in mouse models of intestinal inflammation, and reduces the frequency of Th17 cells isolated from primary intestinal samples of IBD patients<sup>21</sup>.

In loci where fine-mapping was less clearly resolved, we searched for likely functional variants, observing a missense variant (CADD=16.5, 50.2% probability of causality) in *PLCG2*. Furthermore, after conditioning on this variant, we discovered a second, independent, likely functional (CADD=34.0, 74.6% probability of causality) missense variant in the same gene ( $P=2\times 10^{-8}$ ). *PLCG2* encodes a phospholipase enzyme that plays a critical role in regulating immune pathway signalling<sup>22</sup>, and has previously been implicated in two autosomal dominant immune disorders. Intragenic deletions in its autoinhibitory domain cause antibody deficiency and immune dysregulation (familial cold autoinflammatory syndrome 3, MIM 614468)<sup>23</sup> and heterozygous missense variants (e.g. p.Ser707Tyr) lead to a phenotype that includes intestinal inflammation<sup>24</sup> (Figure 1b).

A more general overlap between candidate IBD GWAS genes and Mendelian disorders of inflammation and immunity has been previously observed in 163 loci discovered at that time<sup>25</sup>. We replicated this finding in our list of 241 loci ( $p < 10^{-6}$ , Supplementary Table 4), and observed that this enrichment is even stronger when considering just the 26 loci where a gene can be confidently implicated by fine-mapping to a coding variant or colocalisation with an eQTL (27% vs 3%,  $p=2\times 10^{-5}$ ). In addition to *PLCG2* we identified an association between Crohn's disease and an intronic variant in *NCF4* ( $P=1.76\times 10^{-8}$ ). This gene encodes p40phox, a component of the NADPH-oxidase system that is responsible for the oxidative burst in innate immune cells and which is a key mechanism of killing phagocytosed bacteria. Rare pathogenic variants in *NCF4* cause autosomal recessive chronic granulomatous disease, characterized by Crohn's disease-like intestinal inflammation and defective ROS production in neutrophils<sup>26</sup>. Our associated variant, rs4821544, had previously been suggestively associated with small bowel Crohn's disease<sup>27,28</sup>, and when we stratified patients by disease location we found that the effect was consistently stronger for small bowel compared to large bowel disease (Supplementary Figure 7).

Among the remaining 21 novel loci we noted three that were within 150kb of integrin genes (*ITGA4*, *ITGAV* and *ITGB8*), while a previously associated locus overlaps with a fourth integrin, *ITGAL*. Furthermore, a recent study demonstrated that there is an IBD specific association that affects expression of *ICAMI*, which encodes the binding partner of *ITGAL*<sup>29</sup>. Integrins are cell adhesion mediators with bi-directional signalling capabilities that play a crucial role in leukocyte homing and cell differentiation in inflammation and cancer<sup>30</sup>. Given the strong candidacy of these genes, we sought potentially causal molecular

mechanisms that would connect the IBD associated SNPs to integrin regulation. Our fine-mapping analysis excluded the possibility that these associations are caused by protein-coding changes, so we next tested for effects of IBD risk SNPs on integrin gene expression in immune cells using twelve publicly available eQTL datasets. While many eQTLs and GWAS signals show some degree of correlation, inferences about causality require more robust statistical co-localization of the two signals. Remarkably, we observed three of our five associations had >90% probability of being driven by the same variants as monocyte-specific stimulus response eQTLs (*ITGA4*,  $P_{LPS\_24hr}=0.984$ ; *ITGAL*,  $P_{LPS\_24hr}=0.980$ ; *ICAM1*,  $P_{LPS\_2hr}=0.961$ ; Supplementary Table 5). A fourth association, *ITGB8*, is difficult to map due to extended linkage disequilibrium in the locus, but shows intermediate evidence of co-localization ( $P_{LPS\_24hr}=0.712$ ) in response to the same stimulus (Figure 2). All four of the IBD risk increasing alleles upregulate expression of their respective genes, suggesting that increased levels of pro-inflammatory cell surface markers in response to stimulus may be a consistent mechanism of action. Proving this hypothesis would require showing that IBD risk alleles causally change stimulus-response expression (e.g. by targeted editing of each allele in cell lines homozygous for the low risk haplotype), and moreover that such changes have physiological relevance to disease processes.

One line of evidence that supports such disease relevance for integrins and their counter-receptors is their recent emergence as important therapeutic targets in IBD. Most promisingly, the monoclonal antibodies vedolizumab and etrolizumab, which target the components of the  $\alpha4\beta7$  dimer (encoded by *ITGA4* and *ITGB7*, and responsible for the gut-homing specificity of certain leukocytes), have demonstrated efficacy in IBD<sup>31–33</sup>. Additionally, an antisense oligonucleotide targeting *ICAM1* has shown promise in the treatment of ulcerative colitis and pouchitis<sup>34</sup>. The importance of gut-selectivity for therapeutic approaches is highlighted by the antibodies that bind the  $\alphaL$  and  $\alpha4$  integrin subunits (encoded by *ITGAL* and *ITGA4*, respectively). Therapies targeting  $\alphaL$  (efalizumab) and  $\alpha4$  (natalizumab) demonstrated potential in Crohn's disease<sup>35,36</sup>, but both medications have been associated with progressive multifocal leukoencephalopathy (PML)<sup>37</sup>. This potentially fatal condition is likely mediated by binding to integrin dimers that are not gut-specific, leading to impaired leukocyte migration to the central nervous system and JC virus infection of the brain. Owing to the risk of PML, efalizumab has been withdrawn from the market and natalizumab is not licensed for Crohn's disease in Europe.

Integrins are not only important in cell trafficking, but can also participate in cellular signalling. For example, the  $\alphaV\beta8$  heterodimer – both subunits of which are encoded by genes which are now within confirmed IBD loci (*ITGAV* and *ITGB8*, respectively) – is a potent activator of TGF $\beta$ <sup>38</sup>, with a range of cell-type specific effects. Furthermore, mice with dendritic-cell specific deletion of this complex had impaired regulatory T cell function and severe colitis<sup>39</sup>, whereas deleting the complex in regulatory T cells themselves prevented them from suppressing pathogenic T cell responses during active inflammation<sup>40</sup>. While no current IBD therapeutics target  $\alphaV\beta8$  directly, promising early results of an oral antisense oligonucleotide to the inhibitory TGF $\beta$ -signalling protein SMAD7<sup>41</sup>, itself encoded by a locus identified by genetic association studies<sup>25</sup>, demonstrate the therapeutic potential of modifying TGF $\beta$  signaling in Crohn's disease.

In addition to the connections to anti-integrin and anti-TGF $\beta$  therapies described above, IBD GWAS have previously implicated loci containing other therapeutically relevant genes, such as those in signalling pathways relevant to the targets of anti-TNF and anti-p40 IBD therapies (Figure 3, Supplementary Table 6). These discoveries have demonstrated that the importance of the biological pathways underlying associations, and their potential therapeutic relevance, are not necessarily reflected in their GWAS effect sizes. For example, the modest odds ratios of the signals near integrin genes (1.10-1.12) required tens of thousands of samples to detect at genome-wide significance. Furthermore, analyses aimed at understanding the specific cellular contexts in which these genes are active in IBD, as well as the risk-increasing direction of effect (e.g. consistent up-regulation of integrins in response to LPS stimulus), are only beginning to bear fruit.

Our study has demonstrated that continuing to pursue GWAS, even in a well studied complex disease like IBD, has the potential to complement other powerful approaches, such as targeted genotyping (via the ImmunoChip) and large-scale genome and exome sequencing. In two cases we have implicated genes in which different variants have previously been shown to cause immune-related Mendelian disorders, echoing a connection made to the very first Crohn's disease risk gene, *NOD2*, in which rare missense mutations cause the autosomal dominant granulomatous disorder Blau syndrome<sup>42</sup>. Finally, while the individual effect sizes of our newly discovered associations are modest, our results show that GWAS continues to deliver new loci, which help understand many aspects of disease biology, including possible mechanisms of known therapies. For example, four IBD associations that plausibly co-localize with changes in integrin expression underscore the value of comprehensive catalogs of the regulatory consequences of GWAS variants in specific cells and contexts. Even when specific genes are implicated, cellular assays with relevance to disease physiology (for example, protein response to bacterial stimulus in colonic organoids) will be needed to achieve the ultimate payoff from prospectively mining these signals for promising targets for new therapeutics.

## Data availability

Genotype data that supports this study has been deposited in the European Genome-phenome Archive (EGA) under the accession code [EGAS00001000924](https://ega-archive.org/studies/EGAS00001000924). Association summary statistics are available from [ftp://ftp.sanger.ac.uk/pub/project/humgen/summary\\_statistics/human/2016-11-07/](ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/human/2016-11-07/).

## Online Methods

### New genome-wide genetic data

**GWAS samples and genotyping**—Following ethical approval by Cambridge MREC (reference: 03/5/012), 11,768 British IBD cases, diagnosed using accepted endoscopic, histopathological and radiological criteria, were consented into the study and genotyped on the Human Core Exome v12.1. 10,484 population control samples genotyped on the Human Core Exome v12.0 were obtained from the Understanding Society Project. Genotypes were called using optiCall<sup>43</sup>.



**GWAS quality control**—We removed variants that did not overlap between the two versions of the chip, had missingness > 5%, a significant difference in call rate between cases and controls ( $P < 1 \times 10^{-5}$ ), deviated from Hardy-Weinberg equilibrium (HWE) in controls ( $P < 1 \times 10^{-5}$ ), or that were affected by a genotyping batch effect (significant association [ $P < 1 \times 10^{-5}$ ] between an outlier group of cases discovered using principal component analysis [ $PC1 < -0.005$ ], and the remainder of the samples). We then removed samples with missingness > 1%, heterozygosity  $\pm 3$  standard deviations from the mean, mismatch between reported and genotypic sex, first-degree relatives or closer (kinship coefficient > 0.177), and non-European samples identified through principal component analysis with HapMap3 populations. After quality control, data were available for 4,474 Crohn's disease, 4,173 ulcerative colitis, 592 IBD-unclassified cases and 9,500 controls for 296,203 variants.

**Whole-genome sequenced samples**—We generated low-coverage whole genome sequences for 4,686 IBD cases and 3,781 population controls from the UK IBD Genetics Consortium (UKIBDGC) and UK10K Consortium, respectively. Detailed information on sequencing, genotype refinement and quality control are described elsewhere<sup>9</sup>.

**Imputation**—These sequences were combined with 2,504 samples from the Phase 3 v5 release of the 1000 Genomes project (2013-05-02 sequence freeze) to create a phased imputation reference panel enriched in IBD-associated variants. We used PBWT44 to impute from this reference panel (114.2 million total variants) into our new GWAS described above.

### Association testing, meta-analysis, and quality control

**Association testing**—Prior to association testing, we removed all samples that were included in previous IBD GWAS meta-analyses (Supplementary Table 1). We then tested for association to ulcerative colitis, Crohn's disease and IBD separately within the sequenced samples and new GWAS using SNPTEST v2.5, performing an additive frequentist association test conditioned on the first ten principal components for each cohort. We filtered out variants with minor allele frequency (MAF) < 0.1%, INFO < 0.4, or strong evidence for deviations from HWE in controls ( $p_{HWE} < 1 \times 10^{-7}$ ).

**Meta-analysis**—We used METAL (release 2011-03-05) to perform a standard error weighted meta-analysis of our sequencing and GWAS cohorts with the publicly available International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) meta-analysis summary statistics<sup>1</sup>, after applying the additional MAF = 0.1%, and INFO = 0.4 filters to the IIBDGC data.

**Quality control**—The output of the fixed-effects meta-analysis was further filtered, and sites with high evidence for heterogeneity ( $I^2 > 0.90$ ) were discarded. Only sites for which all cohorts passed our quality control filters were included in our analysis. In addition, we discarded genome-wide significant variants for which the meta-analysis p-value was not lower than all of the cohort-specific p-values.

**LD score regression**—We performed LD score regression using LDSC v1.0.0 and European linkage disequilibrium (LD) scores from the 1000 Genomes Project (downloaded from [https://data.broadinstitute.org/alkesgroup/LDSCORE/eur\\_w\\_ld\\_chr.tar.bz2](https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2)) on our filtered meta-analysis summary statistics for all sites with INFO > 0.95. This INFO threshold is to avoid confounding due to poor imputation, as recommended by the authors<sup>45</sup>.

### Locus definition

**Computing LD windows**—An LD window was calculated for every genome-wide significant variant in any of the three traits (Crohn's disease, ulcerative colitis, IBD), defined by the left-most and right-most variants that are correlated with the main variant with an  $r^2$  of 0.6 or more. The LD was calculated in the GBR and CEU samples from the 1000 Genomes Phase 3, release v5 (based on 20130502 sequence freeze and alignments). Loci with overlapping LD windows, as well as loci whose lead variants were separated by 500kb or less, were subsequently merged, and the variant with the strongest evidence of being associated was kept as the lead variant for each merged locus.

**Identifying novel loci**—A locus was annotated as known if it contained at least one variant previously reported at genome-wide significance (irrespective of the LD between that variant and the most associated variants in the locus). To ensure that putatively novel signals were not due to long-range LD with variants in previously reported loci, we conducted conditional analysis in our new GWAS for all variants in loci which were less than 3Mb away from a known locus. Putatively novel loci already known in a lower order IBD trait (e.g. a previously known Crohn's disease locus coming up as an IBD locus) were also removed from this list. This did not apply where, for example, a known Crohn's disease locus was now associated with ulcerative colitis, or vice versa.

### Fine-mapping

Approximate Bayes factors were calculated from the meta-analysis effect sizes and standard errors described above by applying equation (2) of Wakefield<sup>46</sup>, assuming a prior variance on the log odds ratios of 0.04 (the default prior used by the software SNPTest, and used by Maller *et al*<sup>47</sup>). We then performed fine-mapping using these Bayes factors as described in Maller *et al* to calculate the posterior that each variant is causal, and the 95% credible set for each association (the smallest set of variants with posteriors that sum to at least 95%). For each association we use the meta-analysis results for the phenotype (Crohn's disease, ulcerative colitis or IBD) specified in Supplementary Table 2. We only consider a locus to be confidently fine-mapped if there are no variants in the Phase 3 v5 release of the 1000 Genomes project (2013-05-02 sequence freeze) in high LD ( $r^2 \geq 0.6$ ) with our hit SNP, but missing from our dataset, and no variants in our data within high LD ( $r^2 > 0.8$ ) that fail during our QC procedure.

### eQTL overlap

**Identifying eQTL overlaps**—Twelve eQTL datasets were searched to identify variants within the 25 newly identified IBD risk loci that are associated with variation in gene expression (Supplementary Table 7). Splice-QTLs based on exon-ratio<sup>48</sup> and transcript-



ratio49–51 were also included in the search where available (Supplementary Table 7). The most significant variant-gene associations were extracted from each eQTL/splice-QTL dataset and were reported as candidates if that variant had  $r^2 > 0.8$  with any of the lead SNPs in the 25 IBD risk loci.

**Testing for co-localization**—We tested for co-localization between IBD association signals and eQTLs using the coloc2 method<sup>52</sup>, implemented in the R package coloc. We used a window size of 250kb on either side of the IBD association, and implemented the default settings as recommended. Each test was repeated using two different values for the prior probability of co-localization,  $p_{12}$ :  $1 \times 10^{-5}$  and  $1 \times 10^{-6}$ .

### Signalling pathway definitions

We identify the following immune pathways as relevant to classes of approved IBD therapeutics: the IL12 and IL23 signalling pathways (ustekinumab<sup>53</sup>), the TNF $\alpha$  signalling pathway (infliximab<sup>54</sup>, adalimumab<sup>55</sup>), and the integrin signalling pathway (vedolizumab<sup>31,32</sup>). Genes involved in these pathways were identified from the Molecular Signatures Database canonical pathways gene sets (C2; <http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=CP>). These gene lists had been previously curated by the Pathway Interaction Database<sup>56</sup>. The integrin signalling gene list was comprised of all unique genes from the following gene sets: integrin beta1 pathway (PID\_INTEGRIN1\_PATHWAY), integrin beta7 pathway (PID\_INTEGRIN5\_PATHWAY) and integrin cell surface interactions (PID\_INTEGRIN\_CS\_PATHWAY). The list of TNF $\alpha$  signalling genes was obtained from PID\_TNF\_PATHWAY and the list of IL-23/IL-12 p40 signalling genes was comprised of all unique genes from the PID\_IL12\_PATHWAY and PID\_IL23\_PATHWAY.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

We would like to thank all individuals who contributed samples to the study. This work was co-funded by the Wellcome Trust [098051] and the Medical Research Council, UK [MR/J00314X/1]. Case collections were supported by Crohn's and Colitis UK. KMdL, LM, CAL, YL, DR, JG-A, NJP, CAA and JCB are supported by the Wellcome Trust [098051; 093885/Z/10/Z; 094491/Z/10/Z]. KMdL is supported by a Woolf Fisher Trust scholarship. CAL is a clinical lecturer funded by the NIHR. We thank Anna Stanton for co-ordinating the Guy's and St Thomas' patient recruitment. We acknowledge support from the Department of Health via the NIHR comprehensive Biomedical Research Centre awards to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and to Addenbrooke's Hospital, Cambridge in partnership with the University of Cambridge. This research was also supported by the NIHR Newcastle Biomedical Research Centre. The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The survey was conducted by NatCen and the genome-wide scan data were analysed and deposited by the Wellcome Trust Sanger Institute. Information on how to access the data can be found on the Understanding Society website <https://www.understandingsociety.ac.uk/>.


### References

1. Liu JZ, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* 2015; 47:979–989. [PubMed: 26192919]

2. Parkes M, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet.* 2007; 39:830–832. [PubMed: 17554261]
3. Yamazaki K, et al. A Genome-Wide Association Study Identifies 2 Susceptibility Loci for Crohn's Disease in a Japanese Population. *Gastroenterology.* 2013; 144:781–788. [PubMed: 23266558]
4. Anderson CA, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet.* 2011; 43:246–252. [PubMed: 21297633]
5. Kenny EE, et al. A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. *PLoS Genet.* 2012; 8
6. Julià A, et al. A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. *Hum Mol Genet.* 2014; 23:6927–6934. [PubMed: 25082827]
7. Yang S-K, et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. *Gut.* 2014; 63:80–87. [PubMed: 23850713]
8. Ellinghaus D, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet.* 2016; 48:510–518. [PubMed: 26974007]
9. Luo Y, et al. Exploring the genetic architecture of inflammatory bowel disease by whole genome sequencing identifies association at ADCY7. *Nat Genet.* (In Press).
10. Walter K, et al. The UK10K project identifies rare variants in health and disease. *Nature.* 2015; 526:82–90. [PubMed: 26367797]
11. 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature.* 2015; 526:68–74. [PubMed: 26432245]
12. Huang H, et al. Association mapping of inflammatory bowel disease loci to single variant resolution. *bioRxiv.* 2015; :028688.doi: 10.1101/028688
13. Ivanov II, et al. The Orphan Nuclear Receptor ROR $\gamma$ t Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells. *Cell.* 2006; 126:1121–1133. [PubMed: 16990136]
14. Wang G, et al. Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8. *PLoS One.* 2015; 10:e0121968. [PubMed: 25799045]
15. Wang G, et al. Cutting edge: Slamf8 is a negative regulator of Nox2 activity in macrophages. *J Immunol.* 2012; 188:5829–5832. [PubMed: 22593622]
16. Kircher M, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* 2014; 46:310–315. [PubMed: 24487276]
17. Luci C, et al. Influence of the transcription factor ROR $\gamma$ mat on the development of NKp46+ cell populations in gut and skin. *Nat Immunol.* 2009; 10:75–82. [PubMed: 19029904]
18. Yang Y, et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. *Nature.* 2014; 510:152–156. [PubMed: 24739972]
19. Sawa S, et al. ROR $\gamma$ t+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. *Nat Immunol.* 2011; 12:320–326. [PubMed: 21336274]
20. Gevers D, et al. The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe.* 2014; 15:382–392. [PubMed: 24629344]
21. Withers DR, et al. Transient inhibition of ROR- $\gamma$ t therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. *Nat Med.* 2016; 22:319–323. [PubMed: 26878233]
22. Fu G, Chen Y, Schuman J, Wang D, Wen R. Phospholipase C $\gamma$ 2 plays a role in TCR signal transduction and T cell selection. *J Immunol.* 2012; 189:2326–2332. [PubMed: 22837484]
23. Ombrello MJ, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. *N Engl J Med.* 2012; 366:330–338. [PubMed: 22236196]
24. Zhou Q, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase C $\gamma$ 2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. *Am J Hum Genet.* 2012; 91:713–720. [PubMed: 23000145]
25. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature.* 2012; 491:119–124. [PubMed: 23128233]


26. Matute JD, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. *Blood*. 2009; 114:3309–3315. [PubMed: 19692703]
27. Rioux JD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet*. 2007; 39:596–604. [PubMed: 17435756]
28. Roberts RL, et al. Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. *Genes Immun*. 2008; 9:561–565. [PubMed: 18580884]
29. Dendrou CA, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. *Sci Transl Med*. 2016; 8:363ra149–363ra149.
30. Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell*. 2002; 110:673–687. [PubMed: 12297042]
31. Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2013; 369:711–721. [PubMed: 23964933]
32. Feagan BG, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013; 369:699–710. [PubMed: 23964932]
33. Vermeire S, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet*. 2014; 384:309–318. [PubMed: 24814090]
34. Hosten TA, Zhao K, Han HQ, Liu G, He XH. Alicaforfen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis. *Gastroenterol Res Pract*. 2014; 7:51–55.
35. James DG, Seo DH, Chen J, Vemulapalli C, Stone CD. Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's disease: An open-label pilot study. *Dig Dis Sci*. 2011; 56:1806–1810. [PubMed: 21170755]
36. Sandborn WJ, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2005; 353:1912–1925. [PubMed: 16267322]
37. Carson KR, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. *Lancet Oncol*. 2009; 10:816–824. [PubMed: 19647202]
38. Travis MA, Sheppard D. TGF- $\beta$  activation and function in immunity. *Annu Rev Immunol*. 2014; 32:51–82. [PubMed: 24313777]
39. Travis MA, et al. Loss of integrin  $\alpha$ (v) $\beta$ 8 on dendritic cells causes autoimmunity and colitis in mice. *Nature*. 2007; 449:361–365. [PubMed: 17694047]
40. Worthington JJ, et al. Integrin  $\alpha$ v $\beta$ 8-Mediated TGF- $\beta$  Activation by Effector Regulatory T Cells Is Essential for Suppression of T-Cell-Mediated Inflammation. *Immunity*. 2015; 42:903–915. [PubMed: 25979421]
41. Monteleone G, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med*. 2015; 372:1104–1113. [PubMed: 25785968]
42. Miceli-Richard C, et al. CARD15 mutations in Blau syndrome. *Nat Genet*. 2001; 29:19–20. [PubMed: 11528384]
43. Shah TS, et al. optiCall: a robust genotype-calling algorithm for rare, low-frequency and common variants. *Bioinformatics*. 2012; 28:1598–1603. [PubMed: 22500001]
44. Durbin R. Efficient haplotype matching and storage using the positional Burrows-Wheeler transform (PBWT). *Bioinformatics*. 2014; 30:1266–1272. [PubMed: 24413527]
45. Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015; 47:291–295. [PubMed: 25642630]
46. Wakefield J. Bayes factors for genome-wide association studies: comparison with P-values. *Genet Epidemiol*. 2009; 33:79–86. [PubMed: 18642345]
47. Wellcome Trust Case Control Consortium. Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat Genet*. 2012; 44:1294–1301. [PubMed: 23104008]
48. Zhernakova D, et al. Hypothesis-free identification of modulators of genetic risk factors. *bioRxiv*. 2015; :033217.doi: 10.1101/033217

49. Battle A, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. *Genome Res.* 2014; 24:14–24. [PubMed: 24092820]
50. Monlong J, Calvo M, Ferreira PG, Guigó R. Identification of genetic variants associated with alternative splicing using sQTLseekeR. *Nat Commun.* 2014; 5:4698. [PubMed: 25140736]
51. Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O. Fast and efficient QTL mapper for thousands of molecular phenotypes. *Bioinformatics.* 2016; 32:1479–1485. [PubMed: 26708335]
52. Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* 2014; 10:e1004383. [PubMed: 24830394]
53. Sandborn WJ, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *N Engl J Med.* 2012; 367:1519–1528. [PubMed: 23075178]
54. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet.* 2002; 359:1541–1549. [PubMed: 12047962]
55. Colombel J-F, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology.* 2007; 132:52–65. [PubMed: 17241859]
56. Schaefer CF, et al. PID: the Pathway Interaction Database. *Nucleic Acids Res.* 2009; 37:D674–9. [PubMed: 18832364]




**Figure 1. Likely causal missense variants.**

For A) SLAMF8 and B) PLCG2, local association results are plotted with point size corresponding to LD to our lead variant and color to fine-mapping probability (purple > 50%, intermediate blue 10-50%, navy blue <10%). Gene body diagrams and protein domain annotations are taken from ENSEMBL, and partial predicted crystal structures for both proteins are obtained from the SWISS-MODEL repository.



**Figure 2. Co-localization of disease association and stimulus response eQTLs in monocytes.** The local pattern of disease association (IBD: (A) *ITGA4*, (B) *ITGB8*, (C) *ICAM1*; (D) UC: *ITGAL*) in grey, and the association of that variant with response to LPS (lipopolysaccharide) stimulation in red. Evidence of co-localization (probability > 70%) is observed for all for signals.





**Figure 3. IBD-associated loci containing genes in immune pathways related to classes of approved therapeutics.**

All IBD loci are divided into the studies where they were first identified<sup>1</sup>. Loci that contain a gene in one of four signalling pathways related to targets of three classes of approved IBD therapeutics (Online Methods) are highlighted, with those where the pathway gene has been confidently identified as the causal IBD gene labelled. Despite the general pattern that effect size decreases from left to right, therapeutically relevant associations continue to be found.

**Table 1**  
**Novel IBD-associated loci.**

Rsid	Chr	Position bp	Left - right Mb	Risk Allele	Non - risk Allele	Risk Allele Frequency in 1000 Genomes CEU +GBR	P <sub>Meta</sub>	OR	95% CI	Phenotype	Implicated gene
rs34687326	1	159799910	159.80 - 159.80	G	A	0.900	$1.06 \times 10^{-08}$	1.18	1.12 - 1.24	CD	<i>SLAMF8</i>
rs59043219	1	209970610	209.97 - 210.02	A	G	0.379	$1.09 \times 10^{-08}$	1.08	1.05 - 1.10	IBD	-
rs6740847	2	182308352	182.31 - 182.33	A	G	0.508	$1.22 \times 10^{-13}$	1.10	1.07 - 1.12	IBD	<i>ITGA4</i>
rs144344067	2	187576378	187.50 - 187.68	A	AT	0.895	$1.29 \times 10^{-08}$	1.12	1.08 - 1.16	IBD	-
rs1811711	2	228670476	228.67 - 228.67	C	G	0.826	$6.09 \times 10^{-09}$	1.14	1.10 - 1.18	UC	-
rs76527535	2	242484701	242.47 - 242.49	C	T	0.745	$2.87 \times 10^{-08}$	1.09	1.06 - 1.12	IBD	-
rs2581828	3	53133149	53.10 - 53.17	C	G	0.597	$6.46 \times 10^{-09}$	1.10	1.07 - 1.13	CD	-
rs2593855	3	71175495	71.16 - 71.19	C	T	0.663	$2.54 \times 10^{-09}$	1.09	1.06 - 1.11	IBD	-
rs503734	3	101023748	100.91 - 101.27	A	G	0.513	$2.67 \times 10^{-08}$	1.07	1.05 - 1.10	IBD	-
rs56116661	3	188401160	188.40 - 188.40	C	T	0.795	$5.67 \times 10^{-10}$	1.14	1.10 - 1.18	CD	-
rs11734570	4	38588453	38.58 - 38.59	A	G	0.368	$4.80 \times 10^{-08}$	1.07	1.05 - 1.10	IBD	-
rs17656349	5	149605994	149.59 - 149.63	T	C	0.466	$1.54 \times 10^{-08}$	1.09	1.06 - 1.13	UC	-
rs113986290	6	19781009	19.72 - 19.83	C	T	0.989	$7.59 \times 10^{-09}$	1.36	1.25 - 1.46	UC	-
rs67289879	6	42007403	42.00 - 42.01	T	C	0.179	$3.04 \times 10^{-08}$	1.09	1.06 - 1.13	IBD	-
rs11768365	7	6545188	6.50 - 6.55	A	G	0.816	$3.88 \times 10^{-08}$	1.09	1.06 - 1.12	IBD	-
rs149169037	7	20577298	20.58 - 20.58	G	A	0.895	$3.26 \times 10^{-08}$	1.14	1.10 - 1.19	IBD	<i>ITGB8</i>
rs243505	7	148435339	148.40 - 148.58	A	G	0.624	$3.04 \times 10^{-10}$	1.08	1.06 - 1.11	IBD	-
rs7911117	10	27179596	27.16 - 27.18	T	G	0.871	$1.84 \times 10^{-08}$	1.14	1.10 - 1.19	UC	-
rs111456533	10	126439381	126.32 - 126.55	G	A	0.829	$1.18 \times 10^{-09}$	1.11	1.08 - 1.14	IBD	-
rs80244186	13	42917861	42.84 - 42.94	C	T	0.111	$3.66 \times 10^{-08}$	1.13	1.09 - 1.18	CD	-
rs11548656	16	81916912	81.91 - 81.92	A	G	0.961	$5.18 \times 10^{-11}$	1.27	1.20 - 1.34	IBD	<i>PLCG2</i>
rs10492862	16	82867456	82.87 - 82.92	A	C	0.308	$1.26 \times 10^{-09}$	1.11	1.08 - 1.15	CD	-
rs4256018	20	6093889	6.08 - 6.10	G	T	0.250	$1.23 \times 10^{-08}$	1.08	1.05 - 1.11	IBD	-
rs138788	22	35729721	35.72 - 35.74	A	G	0.418	$2.95 \times 10^{-08}$	1.09	1.06 - 1.13	UC	-
rs4821544	22	37258503	37.26 - 37.26	C	T	0.321	$1.76 \times 10^{-08}$	1.10	1.07 - 1.13	CD	-

**Table 2**  
**Variants fine-mapped to >50% probability of being causal in their given signal.**

Rsid	Chr	Position (bp)	P <sub>Causal</sub>	Effect	Credible set size	Phenotype	P <sub>Meta</sub>	Locus type
rs34687326	1	159799910	1.000	SLAMF8 p.Gly99Ser (missense)	1	CD	$1.06 \times 10^{-08}$	Novel
rs4845604	1	151801680	0.999	RORC (intronic)	1	IBD	$7.09 \times 10^{-14}$	Known
rs1811711	2	228670476	0.914		2	UC	$6.09 \times 10^{-09}$	Novel
rs56116661	3	188401160	0.561	LPP (intronic)	11	CD	$5.67 \times 10^{-10}$	Novel
rs11548656	16	81916912	0.502	PLCG2 p.His244Arg (missense)	3	IBD	$5.18 \times 10^{-11}$	Novel
rs1143687	16	81922813	0.746	PLCG2 p.Arg268Trp (missense)	5	IBD	$3.83 \times 10^{-08}$	Novel
rs4821544	22	37258503	0.804	NCF4 (intronic)	2	CD	$1.76 \times 10^{-08}$	Novel